See what’s changing first. Know which accounts matter next.
Fundz catches funding rounds before they’re announced, and acquisitions, new executives, hiring shifts and contract wins as they happen. It weighs them against your ideal customer profile and delivers a ranked shortlist every morning, with the evidence, the reason to reach out and the decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Link Cell Therapies upsizes Series A financing to $90M to advance logic-gated CAR-T therapies for solid tumors and hematologic malignancies.
Amount Raised
$30 Million
Round Type
Series A
South San FranciscoBiotechnologyHealth CareTherapeuticsDescription
Link Cell Therapies announced a $30 million expansion of its Series A financing, upsizing the round from $60 million to $90 million. The company initiated clinical dosing for LNK001, its lead AND-gated CAR-T therapy targeting CAIX and ENPP3 in a Phase 1 study at MD Anderson Cancer Center for advanced clear cell renal cell carcinoma. The additional capital will advance a second solid tumor program in colorectal cancer and expand the overall pipeline. The company also announced three executive leadership additions, including a new CEO.
Fundz sees it the moment Link Cell Therapies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansLink Cell Therapies raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.